Near-Infrared Fluorescence Nanoparticles for Targeted O*

用于靶向 O* 的近红外荧光纳米颗粒

• 批准号: 7127285
• 负责人: CHUN LI
• 金额: $ 59.83万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-29 至 2010-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7127285
• 关键词: Kaposi' s sarcoma; angiogenesis; athymic mouse; autoradiography; bioimaging /biomedical imaging; biomarker; cell line; chemical synthesis; contrast media; crosslink; cytotoxicity; diagnosis design /evaluation; early diagnosis; enzyme activity; fluorescence microscopy; infrared spectrometry; integrins; melanoma; molecular /cellular imaging; nanotechnology; neoplasm /cancer blood supply; neoplasm /cancer radiodiagnosis; optics; particle; pharmacokinetics; polyethylene glycols; polymers; xenotransplantation

DESCRIPTION (provided by applicant): Near-infrared fluorescence (NIRF)-based optical imaging of human cancers has several advantages over standard imaging techniques in that it is extremely sensitive, inexpensive, and robust; involves no harmful radiation; and allows real-time visualization. The development of well-validated NIRF imaging probes may lead to this new modality becoming clinically viable for molecular imaging. Recent advances in nanotechnology are likely to substantially accelerate the discovery of new NIRF imaging agents that can not only provide increased signal intensity, but also target or "report" both the presence and the biologic activity of tumor-specific biomarkers. In this application, U. T. M. D Anderson Cancer Center, a leading institution in cancer research and patient care, and Eastman Kodak Co., a world leader in the fabrication of optical dyes and nanoparticles, will team to develop novel nanoparticles for molecular optical imaging applications. Our goals are to systematically investigate the in vivo pharmacologic properties of nanoparticles derived from Kodak's platform technology, and to design and develop nanoparticles that use targeting, enzyme activation, or a combination of both features to achieve significant improvements in the sensitivity and specificity of cancer detection. Our specific aims are 1) to synthesize and characterize polymer-shelled silica nanoparticles and cross-linked PEG nanoparticles suitable for NIRF imaging; 2) to establish the effect of particle characteristics on the pharmacokinetics, biodistribution, clearance, extravasation, and intratumoral distribution of NIRF nanoparticles; 3) to establish the stability and signal intensity of NIRF nanoparticles in vivo and the specificity of their retention in tumors; 4) to construct NIRF nanoparticles targeted to angiogenic blood vessels and to tumor cell-associated surface receptors; and 5) to develop smart, activatable NIRF nanoparticles and to combine homing ligand and molecular beacon designs in a single nanoparticulate system. By using a combination of nuclear and optical imaging, autoradiography, and fluorescence microscopy, we expect to provide detailed insights into the pharmacologic properties of NIRF nanoparticles, with the ultimate goal of obtaining nanoparticles that are effective and practical for molecular optical imaging of human cancers.

描述（由申请人提供）： 基于近红外荧光（NIRF）的人类癌症光学成像与标准成像技术相比具有几个优点，因为它非常灵敏，价格低廉，功能强大;不涉及有害辐射;并允许实时可视化。经过充分验证的NIRF成像探针的发展可能会导致这种新的模式成为临床上可行的分子成像。 纳米技术的最新进展可能会大大加速新的NIRF成像剂的发现，这些成像剂不仅可以提供增加的信号强度，而且还可以靶向或“报告”肿瘤特异性生物标志物的存在和生物活性。在本申请中，U. T. M. D安德森癌症中心，一个领先的机构，在癌症研究和病人护理，和伊士曼柯达公司，作为光学染料和纳米粒子制造领域的世界领先者，将与该公司合作开发用于分子光学成像应用的新型纳米粒子。我们的目标是系统地研究来自柯达平台技术的纳米颗粒的体内药理学特性，并设计和开发使用靶向、酶激活或两者结合的纳米颗粒，以显著提高癌症检测的灵敏度和特异性。我们的具体目标是：1）合成和表征聚合物壳二氧化硅纳米颗粒和交联PEG纳米颗粒，适用于NIRF成像; 2）建立颗粒特性对NIRF纳米颗粒的药代动力学、生物分布、清除、外渗和肿瘤内分布的影响; 3）建立NIRF纳米颗粒在体内的稳定性和信号强度以及它们在肿瘤中保留的特异性; 4）构建靶向血管生成血管和肿瘤细胞相关表面受体的NIRF纳米颗粒;和5）开发智能的、可活化的NIRF纳米颗粒并在单个纳米颗粒系统中组合联合收割机归巢配体和分子信标设计。通过使用核和光学成像，放射自显影和荧光显微镜的组合，我们希望提供详细的见解NIRF纳米粒子的药理学特性，与获得的纳米粒子是有效的和实用的人类癌症的分子光学成像的最终目标。